RONNIE POLLARD: Open Payments
NPI 1104871243 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,269 in 28 payments from 13 companies in 2025. Trend: 2023 $110 · 2024 $16,203 · 2025 $6,269
Speaker / faculty: $5,288Food & beverage: $981
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $5,311 |
| Alkermes, Inc. | 6 | $167 |
| Otsuka America Pharmaceutical, Inc. | 3 | $155 |
| Axsome Therapeutics, Inc. | 2 | $139 |
| Corium, LLC | 4 | $117 |
| Janssen Pharmaceuticals, Inc | 1 | $112 |
| Neurocrine BioSciences, Inc. | 2 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $57 |
| ABBVIE INC. | 1 | $24 |
Products named: UZEDY, REXULTI, ARISTADA, Auvelity, Azstarys, SPRAVATO, INGREZZA, FANAPT.
Industry payments across TX — which companies pay providers there.
